Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics

被引：15

作者：

Jiang, Yuxiao ^{[1
,2
]}

Wu, Lili ^{[1
,2
,3
]}

Zhu, Xiaopeng ^{[1
,2
]}

Bian, Hua ^{[1
,2
]}

Gao, Xin ^{[1
,2
]}

Xia, Mingfeng ^{[1
,2
,4
]}

机构：

[1] Fudan Univ, Zhongshan Hosp, Dept Endocrinol & Metab, 180 Fenglin Rd, Shanghai 200032, Peoples R China

[2] Fudan Univ, Fudan Inst Metab Dis, 180 Fenglin Rd, Shanghai 200032, Peoples R China

[3] Guangxi Med Univ, Canc Hosp, Dept Integrated Med, Nanning, Peoples R China

[4] Fudan Univ, Zhongshan Hosp, Dept Endocrinol & Metab, Wusong Branch, Shanghai, Peoples R China

来源：

LIPIDS IN HEALTH AND DISEASE | 2024年 / 23卷 / 01期

关键词：

Metabolic dysfunction-associated fatty liver disease; Hepatic lipid metabolism; Multisystem disease; Pathophysiology; Medications; Clinical trials; TRIGLYCERIDE TRANSFER PROTEIN; NONALCOHOLIC STEATOHEPATITIS; DOUBLE-BLIND; HEPATIC STEATOSIS; RECEPTOR AGONIST; CONTROLLED-TRIAL; OBESE MICE; OBETICHOLIC ACID; BEMPEDOIC ACID; ADIPOSE-TISSUE;

D O I：

10.1186/s12944-024-02092-2

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease that affects over 30% of the world's population. For decades, the heterogeneity of non-alcoholic fatty liver disease (NAFLD) has impeded our understanding of the disease mechanism and the development of effective medications. However, a recent change in the nomenclature from NAFLD to MASLD emphasizes the critical role of systemic metabolic dysfunction in the pathophysiology of this disease and therefore promotes the progress in the pharmaceutical treatment of MASLD. In this review, we focus on the mechanism underlying the abnormality of hepatic lipid metabolism in patients with MASLD, and summarize the latest progress in the therapeutic medications of MASLD that target metabolic disorders.

引用

页数：13

共 138 条

[91]

Pereira IVA, 2011, EXPERT REV GASTROENT, V5, P245, DOI [10.1586/egh.11.22, 10.1586/EGH.11.22]

[92] Mitochondria in steatohepatitis [J].